Medscape InDiscussion: Myelofibrosis

Join Drs Tania Jain and Pankit Vachhani as they discuss the nuance involved in the risk stratification of myelofibrosis and the latest research in prefibrotic myelofibrosis. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999593. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Primary Myelofibrosis: Risk Stratification by IPSS Identifies Patients With Poor Clinical Outcome https://pubmed.ncbi.nlm.nih.gov/23644853/ DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status https://pubmed.ncbi.nlm.nih.gov/21149668/ Predicting Survival After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model https://pubmed.ncbi.nlm.nih.gov/32717433/ New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment https://pubmed.ncbi.nlm.nih.gov/18988864/ GIPSS: Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/29654267/ Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project https://ashpublications.org/blood/article/124/21/405/115226/Mutation-Enhanced-International-Prognostic-Scoring MIPSS70+ v2.0 Predicts Long-Term Survival in Myelofibrosis After Allogeneic HCT With the Flu/Mel Conditioning Regimen https://pubmed.ncbi.nlm.nih.gov/30622146/ MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/29708808/ U2AF1 Mutation Types in Primary Myelofibrosis: Phenotypic and Prognostic Distinctions https://pubmed.ncbi.nlm.nih.gov/29535431/ A Clinical-Molecular Prognostic Model to Predict Survival in Patients With Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/28561069/ MYSEC Prognostic Model Risk Calculator (MYSEC-PM) http://www.mysec-pm.eu/ A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35130339/ Survival Following Allogeneic Transplant in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/32384540/ A Simple Prognostic System in Patients With Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation: A CIBMTR/EBMT Analysis https://pubmed.ncbi.nlm.nih.gov/37134306/ SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/38341324/ IPSET Thrombosis Risk for ET https://thehematologist.org/ipset-thrombosis/

Join Drs Tania Jain and Aaron Gerds as they discuss the latest developments in clinical trials and investigational therapeutics for MPNs. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999594. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Primary Myelofibrosis https://emedicine.medscape.com/article/197954-overview Myeloproliferative Neoplasms https://www.ncbi.nlm.nih.gov/books/NBK531464/ Bromodomain and Extraterminal (BET) Proteins: Biological Functions, Diseases, and Targeted Therapy https://pubmed.ncbi.nlm.nih.gov/37926722/ Long-Term Survival in Patients Treated With Ruxolitinib for Myelofibrosis: COMFORT-I and -II Pooled Analyses https://pubmed.ncbi.nlm.nih.gov/28962635/ Rampal RK, Grosicki S, Chraniuk S, et al. Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve patients with myelofibrosis: results of the MANIFEST-2 randomized, double-blind, phase 3 study. Program and abstracts of the 65th American Society of Hematology Annual Meeting and Exposition; December 10, 2023; San Diego, California. Abstract 628. https://ash.confex.com/ash/2023/webprogram/Paper179141.html Pemmaraju N, Mead AJ, Somervaille T CP, et al.Transform-1: A randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis. Program and abstracts of the 65th American Society of Hematology Annual Meeting and Exposition; December 10, 2023; San Diego, California. Abstract 620. https://ash.confex.com/ash/2023/webprogram/Paper173509.html Defining Disease Modification in Myelofibrosis in the Era of Targeted Therapy https://pubmed.ncbi.nlm.nih.gov/35499819/ A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35130339/ Imetelstat in Patients With Lower-Risk Myelodysplastic Syndromes Who Have Relapsed or Are Refractory to Erythropoiesis-Stimulating Agents (IMerge): A Multinational, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/38048786/

Join Drs Tania Jain and Lindsay Rein as they discuss the current treatment landscape and their approach to treating patients with myelofibrosis. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999595. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Primary Myelofibrosis https://emedicine.medscape.com/article/197954-overview Myeloproliferative Neoplasms https://www.ncbi.nlm.nih.gov/books/NBK531464/ Acute Myeloid Leukemia (AML) Treatment Protocols https://emedicine.medscape.com/article/2004793-overview Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-Phase Myelofibrosis With an IDH2 Mutation https://clinicaltrials.gov/study/NCT04281498 Momelotinib Versus Danazol in Symptomatic Patients With Anaemia and Myelofibrosis (MOMENTUM): Results From an International, Double-Blind, Randomised, Controlled, Phase 3 Study https://pubmed.ncbi.nlm.nih.gov/36709073/ Pacritinib Is a Potent ACVR1 Inhibitor With Significant Anemia Benefit in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/37552106/ Safety and Efficacy of Luspatercept for the Treatment of Anemia in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/38820422/ Venetoclax With Azacitidine or Decitabine in Blast-Phase Myeloproliferative Neoplasm: A Multicenter Series of 32 Consecutive Cases https://pubmed.ncbi.nlm.nih.gov/33844862/ Interferon Therapy in Myelofibrosis: Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/32669244/

Join Drs Tania Jain and Raajit Rampal as they discuss TP53, post-MPN AML, and high-risk MPNs in the context of myelofibrosis. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999596. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Primary Myelofibrosis https://emedicine.medscape.com/article/197954-overview Myeloproliferative Neoplasms https://www.ncbi.nlm.nih.gov/books/NBK531464/ Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies https://pubmed.ncbi.nlm.nih.gov/36632576/ Updated Safety and Efficacy Data From the Phase 3 MANIFEST-2 Study of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients With Myelofibrosis https://meetings.asco.org/abstracts-presentations/231688 Next Generation Sequencing in MPNs. Lessons From the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses https://pubmed.ncbi.nlm.nih.gov/32781570/ The MDM2 Antagonist Idasanutlin in Patients With Polycythemia Vera: Results From a Single-Arm Phase 2 Study https://ashpublications.org/bloodadvances/article/6/4/1162/483223/The-MDM2-antagonist-idasanutlin-in-patients-with Venetoclax With Azacitidine or Decitabine in Blast-Phase Myeloproliferative Neoplasm: A Multicenter Series of 32 Consecutive Cases https://pubmed.ncbi.nlm.nih.gov/33844862/ Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation Versus Nontransplantation Therapies in Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/33798769/ Genomic Analysis of Primary and Secondary Myelofibrosis Redefines the Prognostic Impact of ASXL1 Mutations: a FIM Study https://pubmed.ncbi.nlm.nih.gov/33666653/ TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes https://pubmed.ncbi.nlm.nih.gov/27959731/ Safety and Efficacy of Combined Ruxolitinib and Decitabine in Accelerated and Blast-phase Myeloproliferative Neoplasms https://pubmed.ncbi.nlm.nih.gov/30563881/ Efficacy and Safety of Combination Therapies vs Monotherapy of Hypomethylating Agents in Accelerated or Blast Phase of Philadelphia Negative Myeloproliferative Neoplasms: a Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/36644935/ Genomic and Functional Analysis of Leukemic Transformation of Myeloproliferative Neoplasms https://pubmed.ncbi.nlm.nih.gov/25516983/ BMP2/SMAD Pathway Activation in JAK2/p53-Mutant Megakaryocyte/Erythroid Progenitors Promotes Leukemic Transformation https://pubmed.ncbi.nlm.nih.gov/35421216/ Single-Cell Multi-omics Identifies Chronic Inflammation as a Driver of TP53-Mutant Leukemic Evolution https://pubmed.ncbi.nlm.nih.gov/37666991/

Join Drs Tania Jain and Jeanne Palmer as they discuss their approach to transplant in myelofibrosis. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999597. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Myelofibrosis and Survival Prognostic Models: A Journey Between Past and Future https://pubmed.ncbi.nlm.nih.gov/36983189/ DIPSS plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status https://pubmed.ncbi.nlm.nih.gov/21149668/ Survival Following Allogeneic Transplant in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/32384540/ Posttransplant Cyclophosphamide vs Tacrolimus-based GVHD Prophylaxis: Lower Incidence of Relapse and Chronic GVHD https://pubmed.ncbi.nlm.nih.gov/37156098/ A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35130339/ Advances in Pharmacotherapy for Myelofibrosis: What Is the Current State of Play? https://pubmed.ncbi.nlm.nih.gov/38738513/ ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/38201581/ Superior Outcomes With Fludarabine-Busulfan (Flu/Bu) Based Conditioning for Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis - A Comparative Analysis by CIBMTR https://ashpublications.org/blood/article/138/Supplement%201/912/482649/Superior-Outcomes-with-Fludarabine-Busulfan-Flu-Bu Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis With Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35158092/ Anti-T-Lymphocyte Globulin Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis After Matched Related or Unrelated Donor Transplantation https://pubmed.ncbi.nlm.nih.gov/38773281/ Donor Types and Outcomes of Transplantation in Myelofibrosis: A CIBMTR Study https://pubmed.ncbi.nlm.nih.gov/38916866/ Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/31288096/

Join Drs Tania Jain and Gabriela Hobbs as they discuss their views on the future of research and patient care in myelofibrosis. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999598. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Risk Stratification in Myelofibrosis: Which Model Should You Use? https://www.medscape.com/viewarticle/999593 MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/29226763/ GIPSS: Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/29654267/ DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status https://pubmed.ncbi.nlm.nih.gov/21149668/ A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35130339/ Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations https://pubmed.ncbi.nlm.nih.gov/38386293/ The Role of Mutated Calreticulin in the Pathogenesis of BCR-ABL1-Negative Myeloproliferative Neoplasms https://pubmed.ncbi.nlm.nih.gov/39337361/ Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs https://pubmed.ncbi.nlm.nih.gov/23071245/

Drs Tania Jain and Ruben Mesa discuss the clinical trials and the future of myelofibrosis research. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002053. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Myeloproliferative Neoplasms (MPNs) Have a Significant Impact on Patients’ Overall Health and Productivity: The MPN Landmark Survey https://pubmed.ncbi.nlm.nih.gov/26922064/ A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/22375971/ The Myelofibrosis Symptom Assessment Form (MFSAF): An Evidence-Based Brief Inventory to Measure Quality of Life and Symptomatic Response to Treatment in Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/19250674/ Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I https://pubmed.ncbi.nlm.nih.gov/28606598/ The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 Patients https://pubmed.ncbi.nlm.nih.gov/21536863/ Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/34138638/ Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35950489/ Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2) https://clinicaltrials.gov/study/NCT04468984 Allogeneic Stem Cell Transplant for Patients With Myeloproliferative Neoplasms in Blast Phase: Improving Outcomes in the Recent Era https://pubmed.ncbi.nlm.nih.gov/33821472/ Efficacy and Safety of Ruxolitinib After and Versus Interferon Use in the RESPONSE Studies https://pubmed.ncbi.nlm.nih.gov/29396713/

Join Drs Tania Jain and Krisstina Gowin as they discuss the role integrative medicine plays in the treatment of myelofibrosis. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002054. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs https://pubmed.ncbi.nlm.nih.gov/23071245/ The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 Patients https://pubmed.ncbi.nlm.nih.gov/21536863/ Comprehensively Understanding Fatigue in Patients With Myeloproliferative Neoplasms https://pubmed.ncbi.nlm.nih.gov/26670597/ The Hallmarks of Cancer https://pubmed.ncbi.nlm.nih.gov/10647931/ Primary Prevention of Cardiovascular Disease With a Mediterranean Diet Supplemented With Extra-Virgin Olive Oil or Nuts https://pubmed.ncbi.nlm.nih.gov/29897866/ The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Feasibility Phase https://pubmed.ncbi.nlm.nih.gov/37214789/ Lifestyle Factors and Cancer: A Narrative Review https://pubmed.ncbi.nlm.nih.gov/38468817/ Online Yoga in Myeloproliferative Neoplasm Patients: Results of a Randomized Pilot Trial to Inform Future Research https://pubmed.ncbi.nlm.nih.gov/31174535/ American Cancer Society Guideline for Diet and Physical Activity for Cancer Prevention https://pubmed.ncbi.nlm.nih.gov/32515498/ Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology-ASCO Guideline https://pubmed.ncbi.nlm.nih.gov/37582238

Join Drs Tania Jain and Brandi Reeves as they discuss primary myelofibrosis and post-ET (essential thrombocythemia) and post-PV (polycythemia vera) myelofibrosis. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002055. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Primary MF https://emedicine.medscape.com/article/197954-overview Pegylated Interferon: The Who, Why, and How https://pubmed.ncbi.nlm.nih.gov/39644027/ Genetic Background of PV https://pubmed.ncbi.nlm.nih.gov/35456443/ Ropeginterferon Alfa-2b vs Standard Therapy for Polycythaemia Vera (PROUD-PV and CONTINUATION-PV): A Randomised, Non-inferiority, Phase 3 Trial and Its Extension Study https://pubmed.ncbi.nlm.nih.gov/32014125/ Insights Into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms https://pubmed.ncbi.nlm.nih.gov/35162937/ Nationwide Prospective Survey of Secondary MF in Japan: Superiority of DIPSS-Plus to MYSEC-PM as a Survival Risk Model https://pubmed.ncbi.nlm.nih.gov/37463903/ Prognostication in Myeloproliferative Neoplasms, Including Mutational Abnormalities https://pubmed.ncbi.nlm.nih.gov/36922447/ ASXL1 Mutations Are Prognostically Significant in PMF, but Not MF Following Essential Thrombocythemia or PV https://pubmed.ncbi.nlm.nih.gov/35020812/ Genomic Analysis of Primary and Secondary MF Redefines the Prognostic Impact of ASXL1 Mutations: A FIM Study https://pubmed.ncbi.nlm.nih.gov/33666653/ Thromboembolic Events in PV https://pubmed.ncbi.nlm.nih.gov/30848334/ Optimal Treatment for Patients With Cavernous Transformation of the Portal Vein https://pubmed.ncbi.nlm.nih.gov/35402447/ Cytoreduction for ET and PV: Who, What, When, and How? https://pubmed.ncbi.nlm.nih.gov/38066871/

Join Drs Tania Jain and Prithviraj Bose as they discuss the available JAK inhibitors and how they use them to treat myelofibrosis. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002056. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Primary Myelofibrosis https://emedicine.medscape.com/article/197954-overview JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/32903304/ You Really Got a Hold on Me https://ashpublications.org/ashclinicalnews/news/6493/You-Really-Got-a-Hold-on-Me A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/22375971/ Overall Survival in the SIMPLIFY-1 and SIMPLIFY-2 Phase 3 Trials of Momelotinib in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35869266/ Biological Basis for Efficacy of Activin Receptor Ligand Traps in Myelodysplastic Syndromes https://pubmed.ncbi.nlm.nih.gov/31961337/ Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis (ODYSSEY) https://clinicaltrials.gov/study/NCT06517875 Biology and Therapeutic Targeting of Molecular Mechanisms in MPNs https://pubmed.ncbi.nlm.nih.gov/36534936/ Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL) https://clinicaltrials.gov/study/NCT03627403 Selinexor Plus Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis: SENTRY Phase 3 Study Design https://pubmed.ncbi.nlm.nih.gov/39911057/ EHA 2023, Abstract 210: An Open-Label, Global, Phase (Ph) 1b/2 Study Adding Navtemadlin (Nvtm) to Ruxolitinib (Rux) in Patients (Pts) With Primary or Secondary Myelofibrosis (Mf) Who Have a Suboptimal Response to Rux https://library.ehaweb.org/eha/2023/eha2023-congress/387910/john.mascarenhas.an.open-label.global.phase.28ph29.1b.2.study.adding.navtemadlin.html Imetelstat in Intermediate-2 or High-Risk Myelofibrosis Refractory to JAK Inhibitor: IMpactMF Phase III Study Design https://pubmed.ncbi.nlm.nih.gov/35510486/ CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms https://pubmed.ncbi.nlm.nih.gov/26175413/ Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose With Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV) https://ashpublications.org/blood/article/144/Supplement%201/4568/533799/Ropeginterferon-Alfa-2b-ROPEG-and-Peginterferon The Characteristics of CALR Mutations in Myeloproliferative Neoplasms: A Clinical Experience From a Tertiary Care Center in Qatar and a Literature Review https://pubmed.ncbi.nlm.nih.gov/38804886/ Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis: A Randomized Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/40065169/ TRANSFORM-1 Trial of Navitoclax in Combination With Ruxolitinib for Myelofibrosis Met Primary but Not Secondary Endpoint https://ashpublications.org/ashclinicalnews/news/7630/TRANSFORM-1-Trial-of-Navitoclax-in-Combination Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/34138638/ Efficacy and Safety of Fedratinib in Patients With Myelofibrosis Previously Treated With Ruxolitinib (FREEDOM2): Results From a Multicentre, Open-Label, Randomised, Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/39265613/ Fedratinib in Patients With Myelofibrosis Previously Treated With Ruxolitinib: An Updated Analysis of the JAKARTA2 Study Using Stringent Criteria for Ruxolitinib Failure https://pubmed.ncbi.nlm.nih.gov/32129512/ Impact of TP53 on Outcome of Patients With Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation https://pubmed.ncbi.nlm.nih.gov/36940410/ SURPASS-ET: Phase III Study of Ropeginterferon Alfa-2b Versus Anagrelide as Second-Line Therapy in Essential Thrombocythemia https://pubmed.ncbi.nlm.nih.gov/35924546/ EXCEED-ET: A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.TPS7088 Ropeginterferon alfa-2b Versus Standard Therapy for Polycythaemia Vera (PROUD-PV and CONTINUATION-PV): A Randomised, Non-inferiority, Phase 3 Trial and Its Extension Study https://pubmed.ncbi.nlm.nih.gov/32014125/ Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial https://pubmed.ncbi.nlm.nih.gov/37126762/

Join Drs Tania Jain and Rachel Salit as they explore evolving definitions of remission, relapse monitoring, and patient-centered transplant decisions in myelofibrosis care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002057. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Primary Myelofibrosis https://emedicine.medscape.com/article/197954-overview Role of Hematopoietic Stem Cell Transplantation in Patients With Myeloproliferative Disease https://pubmed.ncbi.nlm.nih.gov/25459177/ Decreasing Chronic Graft-Versus-Host Disease Rates in All Populations https://pubmed.ncbi.nlm.nih.gov/39167805/ Diagnosis and Evaluation of Prognosis of Myelofibrosis: A British Society for Haematology Guideline https://pubmed.ncbi.nlm.nih.gov/37932932/ Prognostic Value of Blasts in Peripheral Blood in Myelofibrosis in the Ruxolitinib Era https://pubmed.ncbi.nlm.nih.gov/32697338/ Acute Myeloid Leukemia (AML) https://emedicine.medscape.com/article/197802-overview CIBMTR Myelofibrosis Medicare Study https://cibmtr.org/CIBMTR/Studies/Research-Programs/Clinical-Trials-Support/Medicare-Clinical-Trials#CMSMF Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/39116296/ Utility of Assessing CD3+ Cell Chimerism Within the First Months After Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia https://pubmed.ncbi.nlm.nih.gov/35064642/ Clearance of Driver Mutations After Transplantation for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/39778169/ Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation https://pubmed.ncbi.nlm.nih.gov/37404772/

What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier interventions, and smarter diagnostics. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002058. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Manipulating Hepcidin in Polycythemia Vera https://pubmed.ncbi.nlm.nih.gov/37383006/ Role of ASXL1 and TP53 Mutations in the Molecular Classification and Prognosis of Acute Myeloid Leukemias With Myelodysplasia-Related Changes https://pubmed.ncbi.nlm.nih.gov/25860933/ Cryptic KMT2A::AFDN Fusion Due to AFDN Insertion Into KMT2A in a Patient With Acute Monoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/40149468/  8p11 Myeloproliferative Syndrome: A Review https://pubmed.ncbi.nlm.nih.gov/20226962/ What's Next? Clinical Trials in Myelofibrosis https://www.medscape.com/viewarticle/1002053 Artificial Intelligence-Based Morphological Fingerprinting of Megakaryocytes: A New Tool for Assessing Disease in MPN Patients https://pubmed.ncbi.nlm.nih.gov/32706893/ Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies https://pubmed.ncbi.nlm.nih.gov/37290996/ The Telomerase Inhibitor Imetelstat Differentially Targets JAK2V617F Versus CALR Mutant Myeloproliferative Neoplasm Cells and Inhibits JAK-STAT Signaling https://pubmed.ncbi.nlm.nih.gov/37941547/ A Novel Application of XPO1 Inhibition for the Treatment of Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/40454401/ BOREAS: A Global, Phase III Study of the MDM2 Inhibitor Navtemadlin (KRT-232) in Relapsed/Refractory Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/36416118/ Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial https://pubmed.ncbi.nlm.nih.gov/37126762/ Center for International Blood & Marrow Transplant Research (CIBMTR) https://cibmtr.org/ Donor Types and Outcomes of Transplantation in Myelofibrosis: A CIBMTR Study https://pubmed.ncbi.nlm.nih.gov/38916866/  Clearance of Driver Mutations After Transplantation for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/39778169/  Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment https://ashpublications.org/blood/article/144/Supplement%201/871/531067/Development-of-a-First-in-Class-CAR-T-Therapy